Meat grown in a lab is food created from cultivating animal cells. The FDA stated that it had "no further questions" regarding the production of cell-cultured chicken meat by California's Upside ...
The US Food and Drug Administration (FDA) has approved the biosimilar ustekinumab ... the biosimilar was as effective as the reference product, with equivalent safety and immunogenicity profiles.
News, September 14, 2011 FDA Approves First Treatment for Congenital Factor XIII Deficiency The FDA has approved the first product intended to prevent bleeding in people with congenital factor ...
HOUSTON — In the summer of 2023, the U.S. Department of Agriculture (USDA) approved lab-grown meat. Two companies were given the OK to distribute their "cultivated meat" to restaurants and ...
The company received approval from the USDA and FDA ... (lab-grown) beef meatball, chicken, and duck directly from animal cells. It received regulatory approval to sell its first chicken product ...
He said the company had wanted to create a product that was “distinctly different” from meat that consumers are already accustomed to, such as chicken, pork or beef. With the parfait, which is ...
Last year in May, the FDA issued a complete response letter to Anktiva plus BCG treatment, citing deficiencies related to the FDA’s pre-license inspection of the company’s third-party ...
Teva intends to launch the product on or after Feb. 21, 2025, according to the companies. The FDA approved Selarsdi for the treatment of moderate-to-severe plaque psoriasis and active psoriatic ...
Opens in a new tab or window The FDA expanded the labels of two CAR T ... were both superior with the CAR-T product. "Carvykti demonstrated remarkable efficacy as a personalized, one-time infusion ...
The FDA has approved Roche’s Alecensa for the treatment of early stage resected non-small cell lung cancer, or NSCLC, with ALK+ mutations. Roche said that the approval makes Alecensa the first ...
The FDA has granted accelerated approval to Ojemda for patients 6 months and older with relapsed or refractory pediatric low-grade glioma with a BRAF fusion or rearrangement, or BRAF V600 mutation.